opportunity knocks

HI all

There's no doubt that PBI must be close to pulling off a commercialisation deal. There's clear evidence in the trading pattern with no one wanting to sell and traders trying to buy on thin volume. I agree with other posts that the company is very confident to take on a buy back.

Just ask yourself this - what is the one thing in common that all fledgling biotech companies share? Answer: they are cash hungry. They just graze on cash and are continually carrying out placements in order to raise revenue to continue research. PBI on the other hand is willing to diminish its cash reserves by buying its own stock back.

Question: What's it going to survive on?
Answer: A secure new revenue stream.

No wonder this stock was picked to outperform others this year. It's had highs of 60c. It's cheap and tightly held.

I hold heaps. Good luck all.

The Cloud

PS check out Cunningham's Securities research on bioMD - ASX: BOD. Interestingly enough bioMD has lowest market cap in the sector at $12 mill with others as high as $163 mill. I'm going to carry out more due diligence on BOD. Keep you posted.